HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.5%

Neg 0% Neu 88.5% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a Buy and maintains $60 price target.